Pharvaris n.v.PHVS.US Overview
PHVS Overall Performance
PHVS AI Analysis & Strategy
PHVS Recent Performance
1.15%
Pharvaris n.v.
0.81%
Avg of Sector
-1.14%
S&P500
PHVS PowerScanner
PHVS Key Information
PHVS Valuation Metrics
PHVS Earnings Table
PHVS Profile
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.